Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence

Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses.  Infection is a common complication after stroke that significantly worsens outc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:F1000Res
Asıl Yazarlar: McCulloch, Laura, Allan, Stuart M., Emsley, Hedley C., Smith, Craig J., McColl, Barry W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: F1000 Research Limited 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820822/
https://ncbi.nlm.nih.gov/pubmed/31700615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.19308.2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller